Precise Molecular Residual Disease (MRD) Test

Precision and sensitivity for deep analysis

Myriad’s Precise MRD test is whole genome sequencing (WGS)-based, enabling the custom selection of hundreds to thousands of targeted variants for deep analysis. It has impressive limits of detection and excellent sensitivity, ensuring exceptional performance. This test is currently available for research use only (RUO).

Precise MRD will help to answer two main questions in several key cancer types:

1

Is my cancer treatment working?

2

Has my cancer recurred?

Myriad supports MRD investigator-initiated trials and other clinical study/trials.
For outreach related to partnering on new or ongoing MRD studies, please contact [email protected]

For investor relations outreach, please contact [email protected]

Precise MRD Press Releases

Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

3/21/24

Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3

2/27/24

Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer

9/18/23

Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform

6/12/23

Featured MRD test research:

Design of high-performance tumor-informed MRD panels from low FFPE tumor input.

Featured MRD test research poster